key: cord-0902529-mt20djoh
authors: Chen, Ganxiao; Li, Xun; Gong, Zuojiong; Xia, Hao; Wang, Yao; Wang, Xuefen; Huang, Yan; Barajas-Martinez, Hector; Hu, Dan
title: Hypertension as a sequela in patients of SARS-CoV-2 infection
date: 2021-04-28
journal: PLoS One
DOI: 10.1371/journal.pone.0250815
sha: d99ae07db1cac1b2c33253073768419790435007
doc_id: 902529
cord_uid: mt20djoh

BACKGROUND: COVID-19 is a respiratory infectious disease caused by SARS-CoV-2, and cardiovascular damage is commonly observed in affected patients. We sought to investigate the effect of SARS-CoV-2 infection on cardiac injury and hypertension during the current coronavirus pandemic. STUDY DESIGN AND METHODS: The clinical data of 366 hospitalized COVID-19-confirmed patients were analyzed. The clinical signs and laboratory findings were extracted from electronic medical records. Two independent, experienced clinicians reviewed and analyzed the data. RESULTS: Cardiac injury was found in 11.19% (30/268) of enrolled patients. 93.33% (28/30) of cardiac injury cases were in the severe group. The laboratory findings indicated that white blood cells, neutrophils, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase were positively associated with cardiac injury marker. Compared with healthy controls, the 190 patients without prior hypertension have higher AngⅡ level, of which 16 (8.42%) patients had a rise in blood pressure to the diagnostic criteria of hypertension during hospitalization, with a significantly increased level of the cTnI, procalcitonin, angiotensin-II (AngⅡ) than those normal blood pressure ones. Multivariate analysis indicated that elevated age, cTnI, the history of hypertension, and diabetes were independent predictors for illness severity. The predictive model, based on the four parameters and gender, has a good ability to identify the clinical severity of COVID-19 in hospitalized patients (area under the curve: 0.932, sensitivity: 98.67%, specificity: 75.68%). CONCLUSION: Hypertension, sometimes accompanied by elevated cTnI, may occur in COVID-19 patients and become a sequela. Enhancing Ang II signaling, driven by SARS-CoV-2 infection, might play an important role in the renin-angiotensin system, and consequently lead to the development of hypertension in COVID-19.

Cardiac injury was found in 11.19% (30/268) of enrolled patients. 93.33% (28/30) of cardiac injury cases were in the severe group. The laboratory findings indicated that white blood cells, neutrophils, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase were positively associated with cardiac injury marker. Compared with healthy controls, the 190 patients without prior hypertension have higher AngII level, of which 16 (8.42%) patients had a rise in blood pressure to the diagnostic criteria of hypertension during hospitalization, with a significantly increased level of the cTnI, procalcitonin, angiotensin-II (AngII) than those normal blood pressure ones. Multivariate analysis indicated that elevated age, cTnI, the history of hypertension, and diabetes were independent predictors for illness severity. The predictive model, based on the four parameters and gender, has a good ability to identify the clinical severity of COVID- 19 

In December 2019, an acute respiratory infectious disease known as "coronavirus disease 2019 (COVID-19)" caused by a novel coronavirus occurred in Wuhan, China [1, 2] . Whole-genome sequencing and systematic analysis showed that this novel. Coronavirus is a distinct clade from beta coronavirus associated with human severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [3] , and was now officially named "SARS-CoV-2" by World Health Organization. Both SARS-CoV and SARS-CoV-2 have been identified to use the angiotensin converting enzyme II (ACE2) receptor as the portal of entry into the affected cell [4, 5] . ACE2, a membrane-bound aminopeptidase, is highly expressed in the heart and lung [6, 7] . Although the main clinical features of COVID-19 are dominated by respiratory symptoms, many patients with severe cardiovascular damage have been reported by our team and others [8, 9] . Besides, patients with underlying cardiovascular diseases might have an increased risk of death [8] . So, understanding the damage to the cardiovascular system caused by SARS-CoV-2 and the underlying mechanisms is of great importance so that these patients can be treated timely, and the mortality can be reduced. In this retrospective cohort study, the clinical data of hospitalized COVID-19-confirmed patients were analyzed to explore the consequences of SARS-CoV-2 infection on the cardiovascular system.

There were 366 COVID-19-confirmed patients enrolled in this study, who were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University, from February 1 to May 1, 2020. Clinical severity was defined for all enrolled COVID-19 patients according to the guidelines of the National Health Commission of China, including four types as mild, moderate, severe, and critical types [10] . We divided the patients into the nonsevere group (mild and moderate types) and the severe group (severe and critical type). Mild type is defined as mild clinical symptoms and no pneumonia manifestation found in imaging. Moderate cases refer to those who present with fever and respiratory tract symptoms, etc. And have pneumonia manifestations found in imaging. Patients considered severe had one of the following three conditions: respiratory distress and respiratory rate higher than 30 times per minute; fingertip blood oxygen saturation less than 93% at rest; partial arterial oxygen pressure (PaO2) / fraction of inspiration oxygen (FiO2) less than 300mmHg. Patients in critical type met one of the following criteria: respiratory failure, requiring mechanical ventilation; shock; multiple organ failure, requiring intensive care management. This study was reviewed and approved by the Medical Ethical Committee of Renmin Hospital of Wuhan University. All participants provided written informed consent and agreed to use their medical records for research purposes.

The clinical signs and laboratory findings were extracted from electronic medical records (Donghua Hospital Information System). Two independent, experienced clinicians reviewed and abstracted the data. The recorded information includes demographic data, potential comorbidities, symptoms, signs, laboratory test results. The serum level of hypersensitive troponin I (cTnI) exceeding >40 pg/mL was considered cardiac injury [11] . Blood pressures were obtained three fixed times in the morning using standard measurement. History of hypertension was defined as brachial blood pressure � 140/90 mmHg or self-reported hypertension medication use before hospitalization. For patients without prior hypertension, elevated blood pressure was defined as blood pressure � 140/90 mmHg more than 3 times during hospitalization.

The screening process for evaluating the effect of SARS-CoV-2 on the cardiovascular system is shown in Fig 1. Serum level of cardiac troponin I (cTnI) was tested in 276 of the 366 patients during hospitalization, among which 8 patients had a history of chronic heart disease (including ischemic heart disease, arrhythmia, valvular disease, and heart failure) and were therefore excluded. Thus, 268 patients were enrolled to evaluate the effect of SARS-CoV-2 on cardiac injury. Of the 366 patients, 278 had complete blood pressure data. Among these, 88 patients had a history of hypertension before hospitalization and were excluded; therefore, 190 patients were grouped to evaluate the effect of SARS-CoV-2 on blood pressure. Among all 366 subjects, 194 subjects had data available on serum level of cTnI and complete blood pressure data. After 

the exclusion of the case with a history of chronic heart disease, 186 cases were included to evaluate the association between cTnI, blood pressure, and clinical severity of COVID-19.

Student's t-test or the Mann-Whitney test was used to compare the mean of continuous variables, Fisher's exact test was used with limited data, the χ2 test was used to compare the proportion of categorical variables. Spearman correlation analysis was used to analyze the correlation between variables. The logistic regression model was used to determine factors associated with the clinical severity of COVID-19, and the analysis of receiver operating characteristic (ROC) curves was constructed according to standard procedures. The Youden index, defined as (sensitivity + specificity)-1, was used to derive a reasonable cut-off value. Calibration of the risk prediction model, comparing the observed and predicted probability, was performed via a visual calibration plot in the R program. A P-value of < 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS software version 21.0 and R version 3.0.

The results showed that the median age of patients with or without cardiac injury was 74 y 

Of the 190 qualified patients, 16 (8.42%) patients had a rise in blood pressure during hospitalization, among which 6 patients were male, and 10 patients were female. As shown in Table 3 , no significant differences were found when comparing the baseline demographics, including age, gender, clinical category, symptoms, and comorbidities between patients with or without elevated blood pressure. Compared with the patients without elevated blood pressure, the level of cTnI and procalcitonin in the 16 patients rose significantly (median [interquartile range]: The Mann-Whitney test was used to compare the differences between non-cardiac injury and cardiac injury groups � P <0.05 is considered statistically significant. Spearman correlation analysis was used to analyze the correlation between the cTnI and other laboratory findings. Table 4 ). Elevated systolic blood pressure was observed in most of the patients, while diastolic blood pressure was in the normal range. The median values of blood pressure and plasma cTnI levels changes of the 16 patients are shown in Fig 2A. Systolic blood pressure and cTnI 

levels had a similar trend with the treatment time. In addition, the blood pressure, cTnI, and white blood cells were continuously monitored in one index case (Fig 2B) . With effective treatment, the patient's condition improved with regards to symptoms and as evident on chest CT. Meanwhile, the systolic blood pressure and white blood cells reverted to the normal range, and the concentrations of cTnI were also gradually decreased. Among the 190 patients without prior hypertension, the serum levels of components in the renin-angiotensin system, including adrenocorticotrophic hormone, renin, angiotensin II (Ang II), and aldosterone, were detected in 28 patients. Table 6 ).

Results of demographic and laboratory findings between the severe and non-severe group, based on guidelines of the National Health Commission of China, are shown in Table 7 Fig 3B) . Discussion SARS-CoV-2 has been identified as a single-stranded enveloped 39 RNA virus belonging to the beta-coronavirus genus of the coronaviridae family [3] . These coronaviruses have a threedimensional spike protein structure protein, which can closely bind the human ACE2 receptor. Therefore, the cells with ACE2 expression may act as target cells and be susceptible to SARS-CoV-2 infection [12] . ACE2 is a membrane-bound aminopeptidase with a vital role in the cardiovascular system [13, 14] . It is, therefore, reasonable to speculate that SARS-CoV-2 will act on the heart and blood vessels, with resultant changes in the cardiovascular system. Serum cardiac troponin assays have been proposed as the recommended marker of cardiac injury in COVID-19 patients [15] . Huang and colleagues find that cTnI is increased substantially in 12.20% (5/41) Wuhan COVID-19 patients, in whom the diagnosis of the virus-related cardiac injury is made [8] . Another previous research also reported that patients with cardiac injury had higher levels of leukocyte counts, C-reactive protein, procalcitonin [16] . In this retrospective study, older patients with diabetes are more likely to suffer from cardiac injury. Our further analysis shows that the level of white blood cells, neutrophils, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase were positively associated with cardiac injury. Besides, the cardiac injury occurred mostly in severe patients. Consequently, we hypothesize that the severe type of COVID-19 characterized by acute inflammation response might be more prone to cardiac injury, especially in patients with preexisting cardiovascular disease. Chronic myocardial injury, acute nonischemic injury, and acute myocardial infarction have all been proposed as causes of cTnI elevation in COVID-19 patients [17] . One case study suggested that direct myopericardial involvement may be a complication of COVID-19 infection [18] .

Understanding of the pathogenesis and complications of COVID-19 is still limited. Due to the lack of viral load quantification results in the literature, it is unclear whether the cardiac injury is directly related to viral load. The recent literature review has shown that although cTnI concentration is only marginally increased in all patients with COVID-19, (values above the 99 th percentile upper reference limit in only 8-12% of positive patients), they are significantly increased in patients with severe disease [19] . Our study further suggests that cardiac injury is an independent risk factor for severe COVID-19 and in combination with age and other statistically significant comorbidities can be used to construct a logistic regression model of COVID-19 severity in hospitalized patients.

Sixteen patients without prior hypertension had a rise in blood pressure during hospitalization, and higher systolic blood pressure was observed in most of the patients. Except for lymphocytes and procalcitonin, no significant differences are found in patients with and without elevated blood pressure. This suggests that abnormal blood pressure may be caused independently of the inflammatory response. The RAS plays a critical role in the cardiovascular system, which includes a classical RAS axis (ACE-Ang II-AT1R pathway) and a non-classical RAS axis (ACE2-Ang 1-7-MasR-based pathway), counter-balancing role of the two axes regulates cardiovascular physiology and disease [20, 21] . ACE2 cleaves Ang II into the Ang 1-7, thus limiting substrate availability in the adverse ACE/Ang II/AT1 receptor axis [22, 23] . Keidar and colleagues found that ACE2 antihypertensive properties may be due to the degradation of angiotensin II [24] . In this study, the laboratory results of RAS show that Ang II level is elevated in the majority of patients without prior hypertension. Compared with normal blood pressure and healthy control groups, Ang II levels were significantly higher in elevated blood pressure groups. A possible mechanism may be the binding of SARS-CoV-2 to ACE2 thereby inhibiting degradation of angiotensin II leading to elevated blood pressure. Another hypothesis is that over activation of the RAS system promotes inflammatory response and cytokine storm, which stimulates the NADH/NADPH oxidase system and triggers cell contraction and vasoconstriction, which then leads to COVID-19 related lung injury. Though the underlying mechanism remains to be elucidated, it is becoming evident that RAS plays a major role in hypertension and COVID-19 infection, as observed in our study. It has been noticed that recombinant human ACE2 is considered as a treatment for patients with COVID-19 (Clinical-Trials.gov ID: NCT04287686). This finding probably shades important implications for future treatment strategies. A recent long-term observational follow-up study of patients with COVID-19 reported nearly one-eighth of patients without previous renal dysfunction developed a reduction in glomerular filtration rate at follow-up. In addition, COVID-19 survivors suffer from relatively higher levels of depression, anxiety, and somatic symptoms (including fatigue or muscle weakness). Severe cases are more susceptible to the development of reduced pulmonary diffusion capacities [25] . Multiple above factors are capable of inducing hypertension in nonhypertensive patients. In addition, the median ages of these patients were 66.5 y/o. It seems that SARS-CoV-2 infection is just a trigger, and age plays a more important role.

On the other hand, sixteen patients with elevated blood pressure show significantly higher levels of cTnI than those normal blood pressure patients. Several studies have demonstrated Ang II direct or indirect effects on cardiomyocytes, some of which were related to pro-inflammatory and pro-hypertrophic responses [26] . Especially when the balance between the ACE and ACE2 was disrupted in COVID-19 patients, the increase in Ang II actions could lead to myocardial inflammation, oxidative stress, and myocyte apoptosis. This hypothesis explains why elevated blood pressure could occur in parallel with mild cardiac injury of COVID-19 patients.

In the present study, we propose that hypertension is probably a sequela of SARS-CoV-2 infection. Although a number of studies of COVID-19 have been reported, there are few reports about the sequela of the disease likely due to lack of long-term clinical follow-up, which also applies to our present research. Next, it is difficult to analyze whether the blood pressure of COVID-19 patients with preexisting hypertension is further increased. Consequently, many patients could not be incorporated in the analysis because of the history of hypertension, which results in a relatively low sample size. Besides, the present study uncovered rising Ang II as one possible mechanism that might result in hypertension in COVID-19. However, due to a lack of detection about ACE2 levels and other components, therefore, we cannot gain a comprehensive view of virus-induced imbalance of the RAS pathway.

In summary, SARS-CoV-2 may impair cardiomyocytes by systemic acute inflammation response, and the cTnI is correlated with the severity of the infection. Accompanied by mild elevation in cTnI, spontaneous hypertension may occur in patients during hospitalization, and could become a sequela of SARS-CoV-2 infection, which may be associated with markedly elevated Ang II levels. 

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China

A Novel Coronavirus from Patients with Pneumonia in China

Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week

Structure analysis of the receptor binding of 2019-nCoV

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20 th Anniversary of the Discovery of ACE2

ACE2 of the heart: From angiotensin I to angiotensin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Large Intra-cardiac Thrombus in a COVID-19 Patient Treated with Prolonged Extracorporeal Membrane Oxygenation Implantation

National Health and Health Commission and State Administration of traditional Chinese medicine. Diagnosis and treatment of pneumonia caused by new coronavirus infection(Trial version 5

Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I

A pneumonia outbreak associated with a new coronavirus of probable bat origin

ACE2: from vasopeptidase to SARS virus receptor

The emerging role of ACE2 in physiology and disease

Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Counter-regulatory renin-angiotensin system in cardiovascular disease

Hypertension: renin-angiotensin-aldosterone system alterations

Angiotensin Converting Enzyme 2: A Double-Edged Sword

Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways

ACE2 activity is increased in monocytederived macrophages from prehypertensive subjects

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology

We gratefully acknowledge contributions from all enrolled patients and related medical staff.

Conceptualization: Ganxiao Chen, Xun Li, Zuojiong Gong, Hao Xia, Yao Wang, Yan Huang, Hector Barajas-Martinez, Dan Hu.